GraniteShares 2x Long COIN Daily ETF vs Regeneron Pharmaceuticals Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.14, while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while GraniteShares 2x Long COIN Daily ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| CONL | REGN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.57 | $812.27 |
52-Week Low | $4.09 | $542.52 |
Market Cap | — | $68.79B |
Enterprise Value | — | $62.74B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.85, down 2.02% on the day, reflecting a challenging year-to-date performance. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while oscillators remain neutral. Recent news highlights the fund's volatility, with significant losses tied to Coinbase stock swings and leveraged daily resets.
The outlook remains highly speculative, offering potential for explosive gains if Bitcoin rallies but carrying substantial risk from daily leverage decay and Coinbase volatility. Investors face amplified losses in downturns, making this suitable only for short-term traders with high risk tolerance.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Trailing returns across standard periods
Latest headlines on both assets
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →